{"entity":{"id":"us-regulatory-exclusivity","kind":"term","name":"US regulatory exclusivity periods","aka":["data exclusivity","market exclusivity","regulatory exclusivity","NCE exclusivity","new chemical entity exclusivity","five-year exclusivity","three-year exclusivity","exclusivity period","exclusivity periods","loss of exclusivity"],"tldr":"Separate from patents, US law gives an approved drug fixed periods during which the FDA will not approve a copy: five years for a new chemical, three for new clinical studies, seven for an orphan indication, twelve for a biologic, plus six months for paediatric studies.","summary":"United States, federal statutes read together. Regulatory exclusivity is granted by the FDA under several statutes: five years of new chemical entity exclusivity and three years of new clinical investigation exclusivity under Hatch-Waxman (1984); seven years of orphan exclusivity under the Orphan Drug Act (1983); twelve years for a reference biologic under the BPCIA (2010); six months of paediatric exclusivity added to all of the above under BPCA (2002); and 180 days of generic exclusivity for the first successful patent challenger. Primary text: the FDA's patents and exclusivity FAQ lists each with its statutory citation.\n\nHow it works: exclusivity runs from approval and does not depend on having a patent, so it matters most for drugs whose patents are weak or expire early, and for biologics where patents are hard to design around. Patents and exclusivity run in parallel; the later date controls when a generic or biosimilar can launch, which is the logic behind the exclusivity timeline on this site. Orphan exclusivity blocks only the same drug for the same indication, and a company can stack orphan indications to extend protection.\n\nThe arguments: the twelve-year biologic term is the longest in the world and the Obama and Trump administrations both proposed cutting it; small-molecule sponsors argue the five-year term is short and that the Inflation Reduction Act's earlier negotiation clock for pills compounds the gap. The European Union's 8+2+1 system and Japan's re-examination period are the comparators.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Test_data_exclusivity","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Test_data_exclusivity"},{"label":"FDA: patents and exclusivity, frequently asked questions","url":"https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity"}],"tags":["law","us"],"related":["hatch-waxman","bpcia","orphan-drug-act","bpca-prea","eu-data-exclusivity","spc","biosimilar","inflation-reduction-act","trips-doha"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-incentive-misalignment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/us-regulatory-exclusivity/","neighbours":{"term":[{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/"},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/"},{"id":"eu-data-exclusivity","kind":"term","name":"EU data and market protection (8+2+1)","route":"/terms/eu-data-exclusivity/"},{"id":"eu-pharma-package","kind":"term","name":"EU pharmaceutical package reform (2023 proposal)","route":"/terms/eu-pharma-package/"},{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/"},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/"},{"id":"novartis-glivec-ruling","kind":"term","name":"Novartis v. Union of India (Glivec, 2013)","route":"/terms/novartis-glivec-ruling/"},{"id":"orphan-drug-act","kind":"term","name":"Orphan Drug Act 1983","route":"/terms/orphan-drug-act/"},{"id":"orphan-designation","kind":"term","name":"Orphan drug designation","route":"/terms/orphan-designation/"},{"id":"bpca-prea","kind":"term","name":"Paediatric drug laws: BPCA and PREA","route":"/terms/bpca-prea/"},{"id":"spc","kind":"term","name":"Supplementary protection certificate (EU)","route":"/terms/spc/"},{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}